Actuate Therapeutics Secures $17.25 Million in Stock Offering

Author: Logan Wright Updated: 09-11-2025 04:20 PM

Actuate Therapeutics Completes Successful Stock Offering

Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company, has recently completed a significant milestone by closing a public offering worth $17.25 million. This announcement marks a crucial step forward in the company’s mission to develop innovative cancer therapies through the inhibition of glycogen synthase kinase-3 beta (GSK-3?).

Details of the Offering

The offering comprised 2,464,286 shares of common stock, with an additional 321,428 shares allocated due to the full exercise of the over-allotment option. The pricing for each share was set at $7.00 before accounting for underwriting discounts and commissions. Importantly, the entire offering was made available for sale directly by Actuate Therapeutics.

Management and Advisers

Lucid Capital Markets took the helm as the sole book-running manager for this offering, while Titan Partners Group acted as the financial advisor. This collaboration underscores the strategic approach Actuate Therapeutics is adopting as it progresses in its field.

Utilization of Proceeds

Following the successful conclusion of the offering, the company indicated that it plans to allocate the net proceeds, which total approximately $15.62 million, towards working capital and for general corporate purposes. This investment is expected to enhance Actuate's capabilities in developing its promising therapies.

Regulatory Framework

The common stock was offered under a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC). The offering followed a final prospectus supplement that has been duly filed with the SEC, ensuring compliance with regulatory standards.

About Actuate Therapeutics, Inc.

Actuate Therapeutics is at the forefront of clinical-stage biopharmaceutical development, focusing on therapies targeting high-impact, hard-to-treat cancers. Its lead investigational drug, elraglusib, is an innovative GSK-3? inhibitor that activates specific molecular pathways crucial for countering tumor growth and enhancing the immune response against cancer.

Therapeutic Innovations

Elraglusib operates by disrupting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR) mechanisms, which are often implicated in cancer resistance to conventional treatments. Additionally, elraglusib has shown potential in boosting anti-tumor immunity by regulating immune checkpoints and functions.

Contact Information

For investor relations, Mike Moyer, Managing Director at LifeSci Advisors, LLC, can be reached for inquiries. Media inquiries can be directed towards Ignacio Guerrero-Ros, Ph.D., or David Schull at Russo Partners, LLC.

Frequently Asked Questions

What is the amount raised by Actuate Therapeutics?

Actuate Therapeutics has successfully raised $17.25 million through its recent public offering.

What will the funds from the offering be used for?

The net proceeds will primarily go towards working capital and general corporate purposes.

Who managed the stock offering?

Lucid Capital Markets served as the sole book-running manager for the offering.

What cancer therapies does Actuate Therapeutics focus on?

The company is dedicated to developing therapies targeting difficult-to-treat cancers, especially through GSK-3? inhibition.

How can I contact Actuate Therapeutics for more information?

Inquiries can be directed to investor relations representative Mike Moyer or media contacts Ignacio Guerrero-Ros, Ph.D., and David Schull at Russo Partners, LLC.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.